Data
Official data in SubjectManager for the following academic year: 2026-2027
Course director
-
Zand Afshin
assistant professor,
Department of Public Health Medicine -
Number of hours/semester
lectures: 12 hours
practices: 0 hours
seminars: 0 hours
total of: 12 hours
Subject data
- Code of subject: OBF-BCK
- 1 kredit
- Biotechnology MSc
- Optional modul
- spring semester
-
Course headcount limitations
min. 5 – max. 20
Available as Campus course for . Campus-karok: GYTK TTK
Topic
Transitioning from a university lab to a professional pharmaceutical company can feel like entering a different world. This course is designed to be your "Career Toolkit," bridging the gap between academic science and the high-standard requirements of the global biotech industry (like Richter Gedeon, Egis, or Teva).
Through interactive workshops and real-world case studies, we explore the "hidden" skills that make a scientist successful: how to work in a regulated environment, the logic of industrial-scale production, and how to handle data with professional integrity. Our goal is to make you "job-ready" by demystifying the professional standards and workflows of modern drug manufacturing.
Lectures
- 1. The Industry Mindset: Transitioning from "Academic Curiosity" to "Standardized Success." - Zand Afshin
- 2. The Gold Standard (GMP): Why "Good Manufacturing Practice" is the language of global pharma. - Zand Afshin
- 3. The Art of the SOP: Learning to write and follow the instructions that keep products safe. - Zand Afshin
- 4. Data Integrity: Managing professional digital notebooks and the "Legal Truth" of a lab result. - Zand Afshin
- 5. Scaling Up Biology: How do we move from a test tube to a 1,000-liter bioreactor? - Zand Afshin
- 6. The Cleanroom World: Navigating the specialized environments of sterile manufacturing. - Zand Afshin
- 7. Downstream Logic: The professional science of purifying a drug at a massive scale. - Nancy Zeineddine
- 8. Quality Control (QC) vs. Quality Assurance (QA): Who checks the medicine, and how? - Nancy Zeineddine
- 9. The Biosimilar Journey: The specific technical challenges of producing "follow-on" biologicals. - Nancy Zeineddine
- 10. Failure as a Teacher: A Group Brainstorming on "Deviation Reports"—what to do when a batch goes wrong. - Nancy Zeineddine
- 11. The Modern Supply Chain: How we keep sensitive biological medicines cold across the globe. - Nancy Zeineddine
- 12. Career Strategy: Interactive Workshop on translating your MSc research into the "industry language" recruiters look for - Nancy Zeineddine
Practices
Seminars
Reading material
Obligatory literature
Literature developed by the Department
Course materials consist of weekly presentation slides covering the lecture topics. These are supplemented by curated "Fact Sheets".Additionally, a "Curriculum Question Bank" consisting of 25 comprehensive questions will be distributed at the start of the semester to guide self-study and provide the basis for both the "Group-Pulse" interactive activity and the final written assessment.
Notes
Recommended literature
Conditions for acceptance of the semester
One assignment at the end of the course
Mid-term exams
It's not required
Making up for missed classes
Not possible
Exam topics/questions
I. Logic: Industry vs. Academia
Why does the industry prioritize "repeatability" over "novelty" in daily production?
What is the logical reason for having a Quality Assurance (QA) department that is independent of production?
Why is "Data Integrity" considered a legal requirement rather than just a good habit?
How does the logic of "Continuous Improvement" (Kaizen) apply to a biotech lab?
Why must every single piece of equipment in a pharma plant be "validated" before use?
II. Application: Professional Standards
In a GMP environment, if an experiment wasn't documented immediately, why is it legally considered "not done"?
Describe a scenario where a Standard Operating Procedure (SOP) prevents a life-threatening medical error.
How do "Single-Use Technologies" (disposable plastic reactors) change the speed of vaccine manufacturing?
How would you apply "Root Cause Analysis" if a batch of protein was contaminated?
Why are environmental monitoring results (air/water purity) just as important as the drug's purity?
III. Mechanism: Scale and Production
Explain the physical challenge of "Oxygen Transfer" when moving from a lab flask to a large bioreactor.
How does a "Clean-In-Place" (CIP) system work to ensure a reactor is sterile without dismantling it?
Describe the role of "Industrial Chromatography" in the final stages of drug purification.
What is the mechanism of a "Cold Chain" and why is it vital for mRNA or Protein stability?
How does a "Fill-Finish" operation ensure that a vial of medicine remains sterile until it reaches the patient?
IV. Diagnostics: Quality Control
What is the difference between a "Release Test" and a "Stability Test" for a new drug?
How does an "Audit Trail" in a digital lab system prove that no one tampered with the results?
Why do we test for "Endotoxins" in injectable medicines, and how is this different from testing for bacteria?
How can "Real-Time Sensors" (PAT) predict if a fermentation is going to fail before it actually happens?
Why is "Method Validation" necessary before a lab test can be used in a professional QC lab?
V. Ethics & Professionalism: The Responsibility of the Scientist
What is the ethical responsibility of a scientist who notices a "deviation" in a production batch?
Why is the "Biosimilar" pathway important for global healthcare equality?
How do "Patent Laws" balance the need for profit with the patient's need for affordable medicine?
Should a company be allowed to hide "negative results" from the regulatory authorities?
Is the environmental impact of plastic "Single-Use" biotech an ethical concern for the future?